The Galleri-Medicare study called REACH (Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity) is a non-randomized, observational study of 50,000 Medicare beneficiaries. The ...
A China-developed KRAS inhibitor led to objective responses in half of patients with previously treated KRAS-mutant non-small cell lung cancer (NSCLC), a prospective non-randomized trial showed.
Antibiotic management of acute uncomplicated appendicitis among children was inferior to appendectomy, a randomized non-inferiority trial showed. For nearly 850 children with available primary outcome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results